2 Common Additions to Multiple Myeloma Therapy Don’t Offer Added Benefit, Study Says
The results of a new clinical trial suggest that two extension treatments that are frequently added to standard therapy care in patients with multiple…
News
Bluebird’s CAR T-cell Therapy Shows Promise in Advanced Multiple Myeloma Patients
Patients with advanced multiple myeloma may benefit from bluebird bio’s novel CAR T-cell therapy bb2121, according to data presented at the 28th EORTC-NCI-AACR Molecular…
Blood Purification Technique Could Offer Therapeutic Benefits for Multiple Myeloma
A technique called extracorporeal blood purification (EBP) could be used to remove certain molecules from the blood and potentially treat different conditions including multiple myeloma and kidney complications associated with it.
Extra Weight in Precancerous Stages Increases Risk of Multiple Myeloma, Study Finds
Patients in a precancerous stage of multiple myeloma would be wise to avoid gaining extra weight, according to new research that shows being overweight or obese…
Ninlaro Granted Conditional Approval by European Commission to Treat Multiple Myeloma
The European Commission has granted conditional marketing authorization to Ninlaro (ixazomib) capsules in combination with Revlimid (lenalidomide) and Decadron (dexamethasone) for multiple myeloma patients who…
Nonspecific Symptoms Including Back Pain Should Be Red Flags for Myeloma, Study Suggests
A combination of nonspecific symptoms, including back pain and weight loss, should alert physicians to the possibility of multiple myeloma. Still, the recognition of symptom patterns…
FDA OKs Darzalex as Combination Therapy for Relapsed or Refractory Myeloma Patients
The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab), in combination with Revlimid (lenalidomide) and dexamethasone, or Velcade (bortezomib) and dexamethasone, for multiple…
Drug Therapy Combo May Have Led to Toxic Epidermal Necrolysis in Multiple Myeloma Patient
Multiple myeloma patients taking the immunomodulatory drug thalidomide may develop a potentially life-threatening dermatologic disorder called toxic epidermal necrolysis (TEN), according to a recent case…
Oral 3-Drug Combo Looks Promising in Treatment-Resistant Myeloma
Combining three well-known oral drugs shows potential for heavily pretreated multiple myeloma patients who have grown resistant to therapy with one of the included drugs, according…
Kyprolis Combo Seen to Improve Life Quality in Relapsed Multiple Myeloma Patients
Adding the proteasome inhibitor Kyprolis (carfilzomib) to the standard two-drug regimen of Revlimid (lenalidomide) and dexamethasone significantly improves health-related quality of life in relapsed multiple…
Recent Posts
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
- Tuspetinib as part of triple-combo therapy showing potential in AML